ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Nov 16, 2022 11:46 JST
Source:
Eisai
Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis
TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis. nippon medac obtained the manufacturing and marketing approval of Japan's first self-administrable subcutaneous injection formulation of MTX, a first line option for the treatment of rheumatoid arthritis, on September 26, 2022. The product is published to Japan's National Health Insurance Drug Price List, today.
The approval of Metoject in Japan is based on the results of a Phase III clinical trial (MC-MTX.17/RA) conducted in Japan by nippon medac to compare the efficacy and safety of Metoject with that of oral MTX, which consisted of a double-blind phase and an extension phase. Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
"Eisai has established a solid franchise and has extensive sales experience in the rheumatoid arthritis area in Japan. By adding Metoject to Eisai's product lineup, we are now able to contribute to rheumatoid arthritis patients in a wide range of stages from the early stages of treatment," said Terushige Iike, Senior Vice President of Eisai and President of Eisai Japan. "We are committed to making further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients."
"Metoject is the first drug for which nippon medac obtained its manufacturing and marketing approval in Japan. It is also the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan," said Hirohisa Iriyama, Representative Director and President of nippon medac. "Although the drug is already widely used overseas, Eisai, which has extensive experience in this area, has been entrusted with the marketing of the drug in Japan, where there are an estimated 700,000 to 800,000 rheumatoid arthritis patients1, allowing us to bring the drug to them as a new treatment option. Nippon medac will continue to make further contributions in this area."
For more information, visit www.eisai.com/news/2022/news202278.html.
Media Inquiries:
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
nippon medac Co., Ltd.
Ueno
TEL: +81-(0)3-6661-6270
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI Concludes Positive Impact Finance Agreement
Mar 29, 2024 19:20 JST
Panasonic Energy and Mazda Enter Agreement Towards Supply of Cylindrical Automotive Lithium-ion Batteries
Mar 29, 2024 17:42 JST
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 15:51 JST
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 15:19 JST
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 29, 2024 14:32 JST
Fujitsu Selected as CDP Supplier Engagement Leader
Mar 29, 2024 10:28 JST
Mazda Production and Sales Results for February 2024
Mar 29, 2024 10:00 JST
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan
Mar 28, 2024 13:52 JST
Toyota Releases Sales, Production, and Export Results for February 2024
Mar 28, 2024 13:35 JST
TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants
Mar 28, 2024 03:00 JST
PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles
Mar 27, 2024 15:13 JST
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
Mar 27, 2024 15:00 JST
TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building
Mar 27, 2024 03:00 JST
JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry
Mar 26, 2024 19:04 JST
La Banque Postale and JCB join forces to elevate payments experience for travellers in France
Mar 26, 2024 15:00 JST
Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin'
Mar 26, 2024 10:24 JST
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
Mar 25, 2024 10:08 JST
Toyota to Open New Tokyo Head Office in Shinagawa in FY2030
Mar 22, 2024 16:15 JST
Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year
Mar 22, 2024 16:04 JST
More Latest Release >>
Related Release
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
3/29/2024 3:51:00 PM JST
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
3/29/2024 3:19:00 PM JST
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
3/29/2024 2:32:00 PM JST
Lifenet and Eisai Co-Develop Dementia Insurance "be"
3/21/2024 5:36:00 PM JST
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
3/21/2024 4:10:00 PM JST
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/6/2024 5:47:00 PM JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
2/21/2024 3:26:00 PM JST
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2024 9:35:00 AM JST
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
2/16/2024 9:31:00 AM JST
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
2/1/2024 6:04:00 PM JST
More Press release >>